ClearPoint Neuro, Inc.CLPTEarnings & Financial Report
Nasdaq · Health Care · Surgical & Medical Instruments & Apparatus
ClearPoint Neuro, Inc. is a medical technology firm specializing in precision neurology solutions. It develops and commercializes intraoperative navigation, targeting and delivery systems for minimally invasive brain surgeries, neurological disorder treatments, and CNS therapy development for global clinical and biopharmaceutical partners.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| The Vanguard Group | 4.50% | 1.2M | flat | 2024-11-12 |
| Bigger Capital Fund, LP | 4.00% | 1.1M | ▲ +0.50pp | 2024-11-08 |
| PTC Therapeutics, Inc. | 3.24% | 894.6K | ▼ -6.52pp | 2024-08-27 |
| BlackRock, Inc. | 1.30% | 366.4K | ▼ -4.70pp | 2024-07-08 |
Insider Transactions
Net 90d: −$302.7K · buys $0 / sells $302.7KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | Richards Timothy T. | Director | Grant | 442 | $9.10 | $4.0K |
| 2026-04-01 | FLETCHER R JOHN | Director | Grant | 1.3K | $9.10 | $11.6K |
| 2026-04-01 | Girin Pascal E R | Director | Grant | 755 | $9.10 | $6.9K |
| 2026-03-19 | BURNETT JOSEPH | CEO and President | Option exercise | 20.9K | $3.24 | $67.9K |
| 2026-03-12 | BURNETT JOSEPH | CEO and President | Option exercise | 84.8K | — | — |
| 2026-03-12 | D'Alessandro Danilo | Chief Financial Officer | Option exercise | 32.6K | — | — |
| 2026-03-12 | SABRA MAZIN | Chief Operating Officer | Option exercise | 26.1K | — | — |
| 2026-03-12 | STIGALL L. JEREMY | Chief Business Officer | Option exercise | 31.0K | — | — |
| 2026-03-11 | D'Alessandro Danilo | Chief Financial Officer | Option exercise | 4.1K | — | — |
| 2026-03-11 | STIGALL L. JEREMY | Chief Business Officer | Option exercise | 8.3K | — | — |
1–10 of 19
Page 1 / 2